Theriva Biologics Inc. (TOVX) is a Healthcare · Biotechnology company listed on NYSE MKT. Price $0.24 (-2.19%), Market cap $0.01B, 52-week low–high $0.18 ~ $0.84.
Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. Its lead product candidate, VCN-01 (zabilugene almadenorepvec), a clinical stage oncolytic human adenovirus that is in Phase 1 clinical trials and Phase 2 VIRAGE trial for patients with pancreatic cancer, head and neck squamous cell carcinoma, ovarian cancer, colorectal cancer, and retinoblastoma. The company also develops VCN-11 for treating solid tumors; SYN-004 (ribaxamase), an oral capsule prophylactic therapy that is in Phase 1b/2a clinical trials for the prevention of acute graft-versus-host-disease (aGVHD) in allogeneic hematop
Financial statements, price targets, institutional (13F) holdings and related news for Theriva Biologics Inc. are updated in real time on BlackAll Trade.
Theriva Biologics Inc. trades at $0.24 (-2.19%). Real-time quotes and charts are available on BlackAll Trade.
Theriva Biologics Inc. has a market cap of about $0.01B.
Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. Its lead product candidate, VCN-01 (zabi